July 14, 2008 - Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced it has received approval from the China State Food and Drug Administration to market Abraxane(R) Paclitaxel for Injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The Phase III clinical trials in the U.S. and China on which this approval was based demonstrated that ABRAXANE doubled the response rate, significantly prolonged time to tumor progression, and in the U.S. trial, significantly improved overall survival versus Taxol(R) in the approved indication.
The details can be read here.
No comments:
Post a Comment